Skip to Main Content

Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment in people born with an inherited form of early onset Alzheimer’s disease.

The Swiss pharma giant has been running the Phase 3 clinical trial for more than a decade, aiming to show that an antibody called crenezumab that targets toxic brain plaques might slow or even prevent Alzheimer’s disease in people born with a specific genetic mutation that typically causes cognitive impairment to begin around age 44.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment